Early results back M-Biotech's implantable glucose monitor
This article was originally published in Clinica
M-Biotech says that proof-of-concept data look promising for its new implantable glucose biosensor. The device, which the firm claims is "unlike other implantable systems", targets a market worth over $1bm in the US alone, says the company.
You may also be interested in...
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.
Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.